These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Metabolism of labetalol by animals and man. Martin LE; Hopkins R; Bland R Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):695-710. PubMed ID: 990152 [TBL] [Abstract][Full Text] [Related]
3. Physiological disposition and metabolism of timolol in man and laboratory animals. Tocco DJ; Duncan AE; Delauna FA; Hucker HB; Gruber VF; Vandenheuvel WJ Drug Metab Dispos; 1975; 3(5):361-70. PubMed ID: 241617 [TBL] [Abstract][Full Text] [Related]
4. Physiological disposition and metabolism of 5-(2',4'-difluorophenyl)salicyclic acid, a new salicylate. Tocco DJ; Breault GO; Zacchei AG; Steelman SL; Perrier CV Drug Metab Dispos; 1975; 3(6):453-66. PubMed ID: 1220 [TBL] [Abstract][Full Text] [Related]
5. The metabolic disposition of (S)-2-(3-tert-butylamino-2-hydroxypropoxy)-3-cyanopyridine in rats, dogs, and humans. Vickers S; Duncan CA; Arison BH; Davies RO; Ferguson R; Zacchei AG Drug Metab Dispos; 1980; 8(3):163-7. PubMed ID: 6104580 [TBL] [Abstract][Full Text] [Related]
6. Physiological disposition and metabolism of (3H)bitolterol in man and dog. Shargel L; Dorrbecker SA Drug Metab Dispos; 1976; 4(1):72-8. PubMed ID: 3404 [TBL] [Abstract][Full Text] [Related]
7. Orally active inhibitors of human leukocyte elastase. I. Disposition of L-683,845 in rats and rhesus monkeys. Vincent SH; Painter SK; Krieter PA; Colletti AE; Lyszack E; Rosegay A; Dean D; Luffer-Atlas D; Miller RR; Cioffe C; Chiu SH Drug Metab Dispos; 1996 Dec; 24(12):1369-77. PubMed ID: 8971144 [TBL] [Abstract][Full Text] [Related]
8. Metabolism of MK-499, a class III antiarrhythmic agent, in rats and dogs. Vickers S; Duncan CA; Slaughter DE; Arison BH; Greber T; Olah TV; Vyas KP Drug Metab Dispos; 1998 May; 26(5):388-95. PubMed ID: 9571219 [TBL] [Abstract][Full Text] [Related]
9. Metabolism and disposition of sulfinalol in laboratory animals. Benziger DP; Fritz A; Edelson J Drug Metab Dispos; 1981; 9(6):493-8. PubMed ID: 6120804 [TBL] [Abstract][Full Text] [Related]
10. Physiological disposition and metabolic fate of a new antiarrhythmic agent, alpha, alpha-dimethyl-4-(alpha, alpha, beta, beta-tetrafluorophenethyl) benzylamine in the rat, dog, monkey, baboon, and man. Zacchei AG; Weidner LL; Besselaar GH; Raftery EB Drug Metab Dispos; 1976; 4(4):387-401. PubMed ID: 8295 [TBL] [Abstract][Full Text] [Related]
11. The disposition of radioactivity after administration of the anthelminthic methyl-14C-5-cyclopropylcarbonyl-2-benzimidazole carbamate (ciclobendazole) to rats and dogs. Brodie RR; Mayo BC; Chasseaud LF; Hawkins DR Arzneimittelforschung; 1977; 27(3):593-8. PubMed ID: 577426 [TBL] [Abstract][Full Text] [Related]
12. The physiological disposition and metabolism of enalapril maleate in laboratory animals. Tocco DJ; deLuna FA; Duncan AE; Vassil TC; Ulm EH Drug Metab Dispos; 1982; 10(1):15-9. PubMed ID: 6124377 [TBL] [Abstract][Full Text] [Related]
13. Disposition and metabolism of finasteride in dogs. Carlin JR; Christofalo P; Arison BH; Ellsworth RE; Rosegay A; Miller RR; Chiu SH; VandenHeuvel WJ Drug Metab Dispos; 1997 Jan; 25(1):100-9. PubMed ID: 9010636 [TBL] [Abstract][Full Text] [Related]
14. The metabolic fate of the coronary vasodilator 4-(3,4,5-Trimethoxycinnamoyl)-1-(N-pyrrolidinocarbonylmethyl)piperazine (cinepazide) in the rat, dog and man. Cameron BD; Chasseaud LF; Hawkins DR; Taylor T Xenobiotica; 1976 Jul; 6(7):441-55. PubMed ID: 997590 [TBL] [Abstract][Full Text] [Related]
15. The metabolic disposition of etodolac in rats, dogs, and man. Cayen MN; Kraml M; Ferdinandi ES; Greselin E; Dvornik D Drug Metab Rev; 1981; 12(2):339-62. PubMed ID: 6461537 [TBL] [Abstract][Full Text] [Related]
16. Disposition of [14C]velnacrine maleate in rats, dogs, and humans. Turcan RG; Hillbeck D; Hartley TE; Gilbert PJ; Coe RA; Troke JA; Vose CW Drug Metab Dispos; 1993; 21(6):1037-47. PubMed ID: 7905382 [TBL] [Abstract][Full Text] [Related]
17. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs. Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117 [TBL] [Abstract][Full Text] [Related]
18. Absorption, disposition kinetics, and metabolic pathways of cyclohexene oxide in the male Fischer 344 rat and female B6C3F1 mouse. Sauer JM; Bao J; Smith RL; McClure TD; Mayersohn M; Pillai U; Cunningham ML; Sipes IG Drug Metab Dispos; 1997 Mar; 25(3):371-8. PubMed ID: 9172957 [TBL] [Abstract][Full Text] [Related]
19. Metabolism of p-(cyclopropylcarbonyl)phenylacetic acid (SQ 20,650). Species Differences. Lan SJ; El-Hawey AM; Dean AV; Schreiber EC Drug Metab Dispos; 1975; 3(3):171-9. PubMed ID: 238816 [TBL] [Abstract][Full Text] [Related]
20. Disposition of MK-852, a fibrinogen receptor antagonist, in rats and dogs. Vickers S; Duncan CA; Yuan AS; Vyas KP Drug Metab Dispos; 1994; 22(4):631-6. PubMed ID: 7956740 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]